

Supplementary Figures and Tables

Landscape of Druggable Molecular Pathways Downstream of Genomic CDH1/Cadherin-1 Alterations in Gastric Cancer

Giorgio Malpeli¹, Stefano Barbi², Giulio Innamorati¹, Mariella Alloggio³, Federica Filippini³, Ilaria Decimo⁴, Claudia Castelli⁵, Roberto Perris⁶, Maria Bencivenga³

¹Department of Surgical, Odontostomatologic, Maternal and Child Sciences, University of Verona, 37134, Verona, Italy

²Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy


³General and Upper GI Surgery Division, Department and of Surgical, Odontostomatologic, Maternal and Child Sciences, University of Verona, 37134 Verona, Italy



⁴Section of Pharmacology, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy.

⁵Pathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy

⁶Department of Biosciences, COMT-Centre for Molecular and Translational Oncology, University of Parma, 43124 Parma, Italy

A







B




C




D




E



F




G




H




I



L



M



N



O




Figure S1 A–O. Gene enrichment analysis on genes correlated with CDH1 mRNA level in 483 GC cases from cBioPortal, Stomach Adenocarcinoma, Firehose Legacy Study. The analysis was performed as follows: a total of 124 gene set collections adding up to 147,592 gene sets were obtained from Enrichr at <https://maayanlab.cloud/Enrichr/> (26). The collections were split into 13 functionally related groups (blocks A–O) and used to perform gene set variation analysis (GSVA) (27). Subsequently, differential enrichment analysis on gene correlation with CDH1 gene expression were performed using *limma* software tool package for each block (28). EP (epithelial phenotype); MP (mesenchymal phenotype).




Figure S2. Representation of genomic data referred to 47 genes downregulated in CDH1-mutated compared to CDH1-wt GC cases. Genomic data of 47 of the 50 genes reported in Table 2, plus CDH1, in 415 GC cases divided into 6 subtypes (from cBioPortal, Stomach Adenocarcinoma, Firehose Legacy study). Genetic data of genes LINC00511, GPR89B and CKS1B were not available. Red-blau color scale indicates variation from higher to lower than diploid samples mRNA level (z-scores, RNA Seq V2 RSEM): light red, upregulated; light blu downregulated. Dark red, gained compared to diploid; dark blu, lost compared to diploid. Grey, invariant.




Figure S3 A–C. Protein interactomes of CDH1-associated transcriptional patterns. Interactomes of proteins (Table 1) upregulated in GC-mutated versus non-mutated GC cases (A), proteins (Table 2) down-regulated in GC-mutated versus non-mutated cases (B), proteins (Table 3) associated with CDH1 upregulation in GC-mutated versus non-mutated GC cases (C). Conditions applied using the software tool STRING: physical interactions; interaction score medium confidence; MCL clustering, inflation 3. Not connected nodes were removed. Clusters are identified by different colors. CDH1 is identified by a rectangle.




Figure S4. CDH1 mRNA levels and copy number status in 483 GC cases. The graph is reproduced from cBioPortal, Stomach Adenocarcinoma, Firehose Legacy Study.




Figure S5. CDH1 transcript levels as a function of gene methylation in 483 GC cases. The graph is reproduced from cBioPortal, Stomach Adenocarcinoma, Firehose Legacy Study.

Table S1. Signaling pathways associated with upregulated and downregulated genes in CDH1-mutated versus non-mutated DGC (diffuse GC) according to the MSigDB database.

Gene Set Name	Description	Genes in Overlap	FDR q-value
Upregulated genes			
LEE_BMP2_TARGETS_UP [772]	Genes up-regulated in uterus upon knockout of BMP2	104	2.7 e-45
BOQUEST_STEM_CELL_UP [261]	Genes up-regulated in freshly isolated CD31- (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.	63	3.6 e-42
BENPORATH_ES_WITH_H3K27ME3 [1114]	Set 'H3K27 bound': genes possessing the trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic stem cells, as identified by ChIP on chip.	118	2.0 e-41
LIM_MAMMARY_STEM_CELL_UP [480]	Genes consistently up-regulated in mammary stem cells both in mouse and human species.	78	1.1 e-39
NABA_MATRISOME [1026]	Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins	103	7.2 e-34
WEST_ADRENOCORTICAL_TUMOR_DN [544]	Down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.	75	3.6 e-33
BENPORATH_SUZ12_TARGETS [1033]	Set 'Suz12 targets': genes identified by ChIP on chip as targets of the Polycomb protein SUZ12 in human embryonic stem cells.	100	1.3 e-31
MEISSNER BRAIN_HCP_WITH_H3K4ME3_AND_H3_H3K27ME3 [1073]	Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation at K4 (H3K4me2) and trimethylation at K27 (H3K27me3) in brain.	101	4.9 e-31
LINDGREN_BLADDER_CANCER_CLUSTER_2B [389]	Genes specifically up-regulated in Cluster IIb of urothelial cell carcinom (UCC) tumors.	57	2.4 e-26
LIU_PROSTATE_CANCER_DN [493]	Genes down-regulated in prostate cancer samples.	62	4.6 e-25
CHICAS_RB1_TARGETS_CONFLUENT [567]	Genes up-regulated in confluent IMR90 cells (fibroblast) after knockdown of RB1 by RNAi.	66	7.4 e-25
BENPORATH_EED_TARGETS [1058]	Set 'Eed targets': genes identified by ChIP on chip as targets of the Polycomb protein EED in human embryonic stem cells.	90	2.5 e-24
SMID_BREAST_CANCER_NORMAL_LIKE_UP [484]	Genes up-regulated in the normal-like subtype of breast cancer.	60	5.7 e-24
CHEN_METABOLIC_SYNDROM_NETWORK [1241]	Genes forming the macrophage-enriched metabolic network (MEMN) claimed to have a causal relationship with the metabolic syndrom traits.	96	4.8 e-23
GOBERT OLIGODENDROCYTE_DIFFERENTIATION_ION_DN [1081]	Genes down-regulated during differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265.	88	1.6 e-22
ONDER_CDH1_TARGETS_2_UP [257]	Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadherin (CDH1) [GeneID=999] knockdown by RNAi.	43	4.7 e-22
SWEET_LUNG_CANCER_KRAS_DN [422]	Genes down-regulated in the Kras2LA mouse lung cancer model with mutated KRAS.	53	2.2 e-21
BENPORATH_PRC2_TARGETS [649]	Set 'PRC2 targets': Polycomb Repression Complex 2 (PRC) targets; identified by ChIP on chip on human embryonic stem cells as genes that: possess the trimethylated H3K27 mark in their promoters and are bound by SUZ12 and EED [GeneID=8726] Polycomb proteins.	65	5.3 e-21
NABA_CORE_MATRISOME [275]	Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans	42	5.3 e-20
RIGGI_EWING_SARCOMA_PROGENITOR_UP [435]	Genes up-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FL1 fusion protein.	51	3.1 e-19
Downregulated genes			
FISCHER_DREAM_TARGETS [968]	Target genes of the DREAM complex.	178	4.8 e-146
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP [1290]	Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1 as inferred from RNAi knockdown of this fusion protein.	176	4.3 e-121
DODD_NASOPHARYNGEAL_CARCINOMA_DN [1408]	Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.	178	6.2 e-117
PUJANA_BRCA1_PCC_NETWORK [1628]	Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA1 across a compendium of normal tissues.	185	8.1 e-114
GOBERT OLIGODENDROCYTE_DIFFERENTIATION_ION_UP [571]	Genes up-regulated during later stage of differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265	124	1.6 e-108
PUJANA_CHEK2_PCC_NETWORK [762]	Genes constituting the CHEK2-PCC network of transcripts whose expression positively correlates (Pearson correlation coefficient, PCC >= 0.4) with that of CHEK2	127	4.8 e-96
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP [323]	Genes up-regulated in MCF7 cells (breast cancer) at 24 h of estradiol treatment.	93	1.3 e-92

SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 [459]	Cluster 6 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts poor survival outcome.	104	3.2 e-92
MARSON_BOUND_BY_E2F4_UNSTIMULATED [692]	Genes with promoters bound by E2F4 in unstimulated hybridoma cells.	119	2.2 e-91
MEBARKI_HCC_PROGENITOR_FZD8CRD_UP [586]	Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on β -catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.	112	5.0 e-91
KOBAYASHI_EGFR_SIGNALING_24HR_DN [252]	Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib after treatment with EGFR inhibitor CL-387785 for 24h.	81	9.0 e-85
BERENJENO_TRANSFORMED_BY_RHOA_UP [551]	Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by expression of constitutively active (Q63L) form of RHOA off plasmid vector.	101	1.0 e-79
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP [154]	Up-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.	66	1.4 e-78
REACTOME_CELL_CYCLE [693]	Cell Cycle	108	7.7 e-78
ROSTY_CERVICAL_CANCER_PROLIFERATION_CL_CLUSTER [140]	The 'Cervical Cancer Proliferation Cluster' (CCPC): genes whose expression in cervical carcinoma positively correlates with that of the HPV E6 and E7 oncogenes; they are also differentially expressed according to disease outcome.	62	7.6 e-75
REACTOME_CELL_CYCLE_MITOTIC [561]	Cell Cycle, Mitotic	97	6.0 e-74
CAIRO_HEPATOBLASTOMA_CLASSES_UP [612]	Genes up-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).	99	1.1 e-72
LEE_BMP2_TARGETS_DN [898]	Genes down-regulated in uterus upon knockout of BMP2	111	3.8 e-69
PUJANA_BRCA2_PCC_NETWORK [424]	Genes constituting the BRCA2-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC ≥ 0.4) with that of BRCA2 across a compendium of normal tissues.	83	1.9 e-67
FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_DN [190]	Genes down-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.	63	1.6 e-66

Table S2. Listing of small drug compounds targeting the top 20 genes found to be up- or down-regulated in CDH1-mutated versus non-mutated GCs, including DGC (diffuse GC).

Rank	Score*	Perturbation	Cell-line	Dose	Time
In all GC					
1	0.1667	FIT	HCC515	10.0μM	24.0h
2	0.1667	GR 127935 hydrochloride	PC3	10.0μM	24.0h
3	0.1667	AMIODARONE HYDROCHLORIDE	A375	10.0μM	24.0h
4	0.1667	GF-109203X	HA1E	12.12μM	24.0h
5	0.1667	Akti-1/2	VCAP	9.1μM	6.0h
6	0.1667	TG101348	VCAP	11.1μM	6.0h
7	0.1667	BRD-K54256913	VCAP	10.0μM	6.0h
8	0.1667	BRD-K94390040	VCAP	10.0μM	6.0h
9	0.1667	isoquercitrin	PC3	10.0μM	24.0h
10	0.1667	trichostatin A	SKB	10.0μM	24.0h
11	0.1667	BRD-K94832621	A549	10.0μM	24.0h
12	0.1667	BRD-A10420615	MCF7	10.0μM	24.0h
13	0.1667	BRD-K11634954	A549	10.0μM	24.0h
14	0.1667	sirolimus	HT29	10.0μM	6.0h
In DGC					
1	0.2222	BRD-K55722623	HEPG2	10.0μM	6.0h
2	0.2222	BRD-K13169950	ASC	10.0μM	24.0h
3	0.1667	AY 9944	HA1E	10.0μM	24.0h
4	0.1667	N9-isopropylolomoucine	A673	122.55μM	6.0h
5	0.1667	Salermide	HT29	120.0μM	24.0h
6	0.1667	Arachidonyl trifluoro-methyl ketone	HT29	80.0μM	24.0h
7	0.1667	piperlongmMine (HPLC)	HT29	10.0μM	24.0h
8	0.1667	piperlongmMine (HPLC)	MCF7	10.0μM	24.0h
9	0.1667	ABT-751	MCF7	10.0μM	24.0h
10	0.1667	BRD-K05649647	NCIH1836	20.0μM	6.0h
11	0.1667	Emetine Dihydrochloride Hydrate (74)	NCIH596	0.63μM	6.0h
12	0.1667	Parthenolide	SW948	10.0μM	6.0h
13	0.1667	BRD-K70871370	HCC515	10.0μM	6.0h
14	0.1667	BRD-K18726304	HEPG2	10.0μM	6.0h

*A score is the overlap between the input differentially expressed genes and the signature differentially expressed genes divided by the effective input, reciprocally adopted as input upregulated genes intersected with the downregulated genes of the datasets and input downregulatedgenes intersected with the corresponding upregulated genes. The analysis was performed through L1000CDS² at <https://maayanlab.cloud/L1000CDS2/#/index>.

Table S3. Listing of best combinations of small drug compounds targeting the genes found to be up- or down-regulated in CDH1-mutated versus non-mutated GCs and DGC (diffuse GC).

Rank	Score*	Combination ⁺
In all GC		
1	0.3333	4. GF-109203X
2	0.3333	7. BRD-K54256913
3	0.3333	13. BRD-K11634954
4	0.3333	4. GF-109203X
5	0.3333	7. BRD-K54256913
6	0.3333	13. BRD-K11634954
7	0.3333	19. radicicol
8	0.3333	16. BRD-K37392901
9	0.3333	19. radicicol
10	0.3333	22. radicicol
11	0.3	1. FIT
12	0.3	2. GR 127935 hydrochloride
13	0.3	3. AMIODARONE HYDROCHLORIDE
14	0.3	5. Akti-1/2
In DGC		
1	0.3889	1. BRD-K55722623
2	0.3889	2. BRD-K13169950
3	0.3889	2. BRD-K13169950
4	0.3333	1. BRD-K55722623
5	0.3333	2. BRD-K13169950
6	0.3333	2. BRD-K13169950
7	0.3333	2. BRD-K13169950
8	0.3333	1. BRD-K55722623
9	0.3333	3. AY 9944
10	0.3333	1. BRD-K55722623
11	0.3333	3. AY 9944
12	0.3333	3. AY 9944
13	0.3333	2. BRD-K13169950
14	0.3333	5. Salermide
		2. BRD-K13169950
		5. Salermide
		9. ABT-751
		3. AY 9944
		3. AY 9944
		4. N9-isopropylolomoucine
		6. Arachidonyl trifluoro-methyl ketone
		7. piperlongumine (HPLC)
		7. piperlongumine (HPLC)
		8. piperlongumine (HPLC)
		8. piperlongumine (HPLC)
		9. ABT-751
		10. BRD-K05649647
		10. BRD-K05649647

*A score is the overlap between the input differentially expressed genes and the signature differentially expressed genes divided by the effective input, reciprocally adopted as input upregulated genes intersected with the downregulated genes of the datasets and input downregulated genes intersected with the corresponding upregulated genes. The analysis was performed through L1000CDS² at <https://maayanlab.cloud/L1000CDS2/#/index>.

⁺The number next to a drug name refers to the position of the individual treatment.